Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q3 FY24 results · Oct–Dec 2023
Lincoln Pharmaceuticals reported revenue from operations of ₹146.45 crore (up 9.5% from Q3 FY23) and net profit of ₹28.04 crore (up 29.7% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 146.45 | 133.77 | +9.5% | 155.99 | −6.1% |
| Other income | 11.02 | 6.36 | +73.3% | 8.69 | +26.7% |
| Total income | 157.47 | 140.12 | +12.4% | 164.68 | −4.4% |
| Profit before tax | 37.71 | 30.51 | +23.6% | 36.87 | +2.3% |
| Net profit for the period | 28.04 | 21.61 | +29.7% | 27.65 | +1.4% |
| EPS, basic (₹) | 14.00 | 10.79 | +29.7% | 13.81 | +1.4% |
| Net margin (%) | 19.1 | 16.2 | 17.7 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 146.45 | 133.77 | +9.5% | 155.99 | −6.1% |
| Other income | 11.02 | 6.36 | +73.3% | 8.69 | +26.7% |
| Total income | 157.47 | 140.12 | +12.4% | 164.68 | −4.4% |
| Profit before tax | 37.71 | 30.52 | +23.6% | 36.87 | +2.3% |
| Net profit for the period | 28.04 | 21.61 | +29.7% | 27.65 | +1.4% |
| EPS, basic (₹) | 14.00 | 10.79 | +29.7% | 13.81 | +1.4% |
| Net margin (%) | 19.1 | 16.2 | 17.7 |
Consolidated
- Filed with BSE
- 21 Feb 2024, 11:53 IST
- Board meeting
- 08 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 Feb 2024, 11:53 IST
- Board meeting
- 08 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE